Ran Nissan

Ran Nissan

Auto-generated profile, based on publicly available information

Ran Nissan

Pharmaceutical Society of Israel, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2018 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
RNRan Nissan
Ran Nissan
GSGalia Spectre
Galia Spectre
AHAvital Hershkovitz
Avital Hershkovitz
HGHefziba Green
Hefziba Green
SSShai Shimony
Shai Shimony
SFShmuel Fuchs
Shmuel Fuchs

1 April 2018 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
AHAvital Hershkovitz
Avital Hershkovitz
CACorina Angel
Corina Angel
SBShai Brill
Shai Brill
RNRan Nissan
Ran Nissan

28 April 2016 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
RNRan Nissan
Ran Nissan
APAlina Poperno
Alina Poperno
GSGideon Y. Stein
Gideon Y. Stein
BSBarak Shapira
Barak Shapira
SFShmuel Fuchs
Shmuel Fuchs
MAMickey Arieli
Mickey Arieli
Detection of Phosphodiesterase Type 5 (PDE-5) inhibitors and their analogues in “100% natural” or “herbal” supplements have been described in numerous reports. However, few reports have been published in relation to actual harm caused by counterfeit erectile dysfunction herbal supplements. We describe a case of a 65-year old male admitted to a tertiary hospital with acute liver toxicity, possibly induced by adulterated “Chinese herbal” supplement “Tiger King” for sexual enhancement. Chemical analysis of the tablets discovered the presence of therapeutic doses of sildenafil with no other herbal components. Other medications were excluded as potential causes of the hepatic impairment. According to the Naranjo adverse drug reaction scale and the Roussel Uclaf Causality Assessment Method (RUCAM) the probability of association of Hepatotoxicity with Sildenafil was “possible” and “probable” respectively (Naranjo score of 4, RUCAM score of 7). Within three days of admission, the patient’s clinical status and liver function improved without any specific treatment. His liver function tests normalized 30 days post discharge. Further pharmacovigilance actions should be taken by regulatory authorities and pharmaceutical companies in order to determine the relation between sildenafil and hepatotoxicity. This case emphasizes the importance of raising public awareness on the potential dangers of “Tiger king” in particular, and other counterfeit medications or herbal supplements of unknown origin.

20 September 2021 in Disability and Rehabilitation
Verified
Journal Article
Closed access
AHAvital Hershkovitz
Avital Hershkovitz
GMGal Maydan
Gal Maydan
RJRonen Ben Joseph
Ronen Ben Joseph
RNRan Nissan
Ran Nissan
To report on serum 25-hydroxyvitamin D (25(OH)D) levels in post-acute hip fractured patients, revealed the associations between serum 25(OH)D levels and hip fractured patients’ baseline characteris...

12 April 2019 in Disability and Rehabilitation
Verified
Journal Article
Closed access
RNRan Nissan
Ran Nissan
SBShai Brill
Shai Brill
AHAvital Hershkovitz
Avital Hershkovitz
Purpose: To follow changes in anticholinergic drug prescriptions throughout hip fractured patients’ rehabilitation; to assess whether a change in anticholinergic burden affects rehabilitation outcome. Methods: Retrospective study of 869 hip fractured patients admitted between January 2011 to October 2015, performed in a post-acute geriatric rehabilitation center. The Anticholinergic Cognitive Burden Scale quantified the anticholinergic burden. Main outcome measures: Functional Independence Measure, motor Functional Independence Measure, Montebello Rehabilitation Factor Score on motor Functional Independence Measure and length of stay. Multiple linear regression analysis tested for independent association between admission anticholinergic burden and anticholinergic burden change during rehabilitation, and rehabilitation outcomes. Results: One hundred and sixty two (18.7%) patients were prescribed additional anticholinergic medications upon discharge; 76 (8.7%) were prescribed fewer. Patients with high admission anticholinergic burden presented with a significantly higher rate of higher education, less likely to reside at home, less independent pre-fracture, exhibited a significantly lower admission and discharge Functional Independence Measure score, a lower Functional Independence Measure score change and a lower Montebello Rehabilitation Factor Score. Admission anticholinergic burden, but not changes in anticholinergic burden during rehabilitation, was found to be independently associated with rehabilitation outcome (discharge FIM score). Conclusions: High admission anticholinergic burden is associated with lower functional ability in hip fractured patients. Changes in anticholinergic drug prescription during rehabilitation were not associated with rehabilitation outcomes.

24 November 2022 in Disability and Rehabilitation
Verified
Journal Article
Closed access
ZKZoya Korotkov
Zoya Korotkov
RNRan Nissan
Ran Nissan
AHAvital Hershkovitz
Avital Hershkovitz
To assess the relationship between anticoagulant use and rehabilitation outcomes in post-acute hip fracture patients. A retrospective study (1/2017 to 5/2019) of 299 hip fractured patients. Functional Independence Measure (FIM) and the motor FIM’s effectiveness. Patients treated with anticoagulation drugs exhibited a significant longer latency time from fracture to surgery (U = –4.37, p < 0.001) and from surgery to rehabilitation (U=–2.27, p = 0.023), and a significantly higher rate of cardiovascular diseases (χ2=0.15, p= 0.023) compared with untreated patients. No significant differences between the two patient groups were found regarding the rate of blood transfusions, perioperative complications (infections, reoperation), or functional outcome measures. Oral anticoagulants are not associated with rehabilitation outcomes of hip fracture patients.